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OBJECTIVES: The reporting of blood pressure (BP) is known to
be affected by errors due to digit preferences or rounding to the
closest multiple of ten. If this occurs completely randomly, esti-
mates of effect will be attenuated and the power of statistical
tests reduced. Systematic bias can also occur if, for instance,
physicians round measurements differentially for high or low
risk patients. We examined this with data taken from an ongoing
naturalistic study of the impact of a hypertension control edu-
cation program. METHODS: Systolic and diastolic blood pres-
sure measurements were reported by physicians at the time of
enrolling hypertensive patients. We derived the distribution of
the terminal digit of the measurements and compared the prob-
ability of reporting a terminal zero when the measurement was
above or below the threshold of BP control (140/90 mm Hg) and
by patients’ baseline characteristics. RESULTS: Analyses were
based on an interim cut of data on 4594 patients, of which
47.5% were male with mean age 56 years (SD = 13.5). There
was clear evidence of digit preference by physicians: e.g., 46.3%
of systolic BP measurements ended with 0, and 43.3% were even
numbers. The probability of a terminal zero was slightly higher
above the systolic BP control threshold: 47.1% above vs. 44.4%
below (p-value = 0.09). Rounded values were also more likely
for females (47.9 vs. 44.6%, p-value = 0.02) and patients 65
years or older (49.7 vs. 45.2%, p = 0.01), but did not differ by
levels of other cardiovascular risk factors. Measurements of dias-
tolic BP were also rounded very frequently (44.6%), but dif-
ferences by patient characteristics were not signiﬁcant.
CONCLUSION: Physicians frequently round to the closest mul-
tiple of ten when reporting BP measurements, and do so slightly
more frequently for female and older patients, and those further
from the threshold deﬁning BP control.
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OBJECTIVES: The ﬁeld of pharmacoeconomics has evolved
rapidly over the past two decades and the methodological rigor
and sophistication found in contemporary pharmacoeconomic
analyses are remarkable. However, many useful analytic methods
have yet to be adopted or fully considered, techniques that may
be particularly well suited for our ﬁeld. One promising method,
long used in economics and physics, is dynamic optimization,
which can identify optimal treatment pathways for patients suf-
fering from diseases with progressive treatment options, both
types and doses, where the value of aggressive treatment is of
interest. Using hyperlipidemia as a case study, we propose mul-
tiple mathematical and statistical methods to identify the optimal
(both cost-minimizing and net beneﬁt-maximizing) hyperlipi-
demia treatment trajectories that consider the options of diet and
exercise and multiple-dose statin therapy to bring a patient, or
population of patients, to a pre-determined cholesterol goal (e.g.
their NCEP goal). METHODS: Discrete-time mathematical pro-
gramming models, both deterministic and stochastic, are devel-
oped to optimize over the combinatorial set of clinically feasible
hyperlipidemia treatment strategies. Contemporary cardiovascu-
lar risk equations, costs, and side effect risk data are used to pop-
ulate the models and programs. RESULTS: Initial results suggest
that optimal (economic) hyperlipidemia treatment strategy varies
based upon patient proﬁle and risk for CVD, but in the major-
ity of cases more aggressive statin therapy results in higher
expected net beneﬁts and lower expected costs than current treat-
ment approaches; speciﬁcally, gradual titration regimens. Analy-
ses considering longer term horizons (e.g., >1 year) tend to
increases net beneﬁt differences more than cost differences.
CONCLUSION: The preliminary evidence in our research sug-
gests that considerable cost savings (and net beneﬁts gains) are
possible if hyperlipidemia patients are treated aggressively to
reduce their cardiovascular risk as quickly as possible. These
methods are generalizable to other disease areas and are useful
in economic evaluation of treatment patterns.
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OBJECTIVES: This research applies factor screening techniques
to a decision tree model of the ﬁrst 30 days following an acute
coronary event. The objective is to determine which input vari-
ables most affect the total cost and to evaluate how well a meta-
model composed of fewer variables can replace the decision tree
model. METHODS: Factor screening techniques are often used
in defense simulations to examine simultaneously many input
variables to identify those with a signiﬁcant effect on a selected
response (output). The original model was built using TreeAge
Pro Health care and parameterized to replicate 30-day results
from the Clopidogrel in Unstable angina to prevent Recurrent
ischemic Events (CURE) trial. The model had 44 input variables
(28 relatively independent factors) comparing 30-day results for
clopidogrel plus aspirin to a hypothetical alternative. Ranges of
uncertainty were assigned to the input variables. A 2 k Fractional
Factorial of Resolution IV (FF) and a Folded-over Sequential
Bifurcation (SB-X) method were used to identify important
factors. A metamodel was generated using a Central Composite
Design and dropping the effects with F-ratio less than 2.0.
RESULTS: Both the FF and SB-X methods identiﬁed the same
seven factors (ﬁve costs and two probabilities). In addition to the
main effects, the metamodel had only two second-order terms,
and no quadratic effects. When a Nearly Orthogonal Latin
Hypercube Design with 256 observations was used to sample the
entire experimental region (including all 28 factors), the reduced
metamodel could account for more than 99% of the variation
observed over the entire experimental region. (Error: 0.702%)
CONCLUSION: Results from the 44-variable decision-tree
model were matched by a nine-term metamodel. When factor
screening can reduce the number inputs that must be speciﬁed,
the data needed to predict responses can be greatly reduced.
Further work investigates factor screening and developing cor-
responding metamodels for stochastic models.
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